Insights
Insights on Biotech Partnering
Selected notes on asset strategy, partnership structures, and cross-border biotech business development.
Editor's note. Kerlann's coverage is selective and principal-led. We write on asset classes and deal-stage partnering where we have active advisory experience — not on every therapeutic modality.
Series · 10-part
Cell Therapy Partnership Strategy
A 10-part series on how cell therapy assets are evaluated, structured, and partnered — written for biotech BD teams and external innovation leads weighing in-licensing, co-development, or acquisition.
Featured
Selected articles
- Cell Therapy Strategy21 August 2025
The Integration Edge
In cell therapy deals, post-signing integration of manufacturing, supply, and clinical operations often decides whether the partnership creates value — well before commercial readiness.
- Oncology Platforms30 July 2025
Platform vs. Product
Platform stories command premiums when they convert to multiple credible products. We look at how partners separate genuine platforms from single-asset programmes wrapped in platform language.
- Deal Structures & Market Entry9 July 2025
Deal Architectures from Landmark Partnerships
Notes on how recent landmark cell therapy and oncology partnerships have been structured — upfronts, biobucks, territory splits, and the contingent value mechanics that actually get exercised.
- Cell Therapy Strategy18 June 2025
Strategic Entry Points for New Cell Therapy Acquirers
For pharma and large biotech entering cell therapy for the first time, the choice between asset acquisition, platform deal, and manufacturing partnership shapes the next five years more than valuation does.
Upcoming
In preparation
- External Partnering
What BD Teams Need Before Reviewing an External Biotech Asset
- External Partnering
Structuring an Out-Licensing Process for a Single Lead Asset
- Oncology Platforms
ADC and ISAC Partnering: Where Payload, Linker, and Target Strategy Meet Deal Terms
- Oncology Platforms
Innate Checkpoint Programmes: What Makes an Asset Partner-Ready Today
- Oncology Platforms
Radiopharmaceutical Assets: Isotope Supply, Site Network, and the Real Deal Constraints
- Oncology Platforms
Therapeutic Cancer Vaccines: Reading the Second Wave of Partnering Interest
- Cell Therapy Strategy
TCR-T and TCR Engagers: Partnering Logic Beyond the CAR-T Playbook
- Oligonucleotide Therapeutics
Positioning Oligonucleotide Assets for Combination Regimens
- Oligonucleotide Therapeutics
HBV Functional Cure: Partnering an Oligonucleotide Backbone into a Combination Story
- China-Originated Innovation
China-Originated Assets: A Western BD Reader's Guide to Diligence
- China-Originated Innovation
Out-Licensing from China: Sequencing US, EU, and Japan Conversations
- Deal Structures & Market Entry
Option-to-License vs. Full Acquisition: When Each Structure Actually Fits
- Deal Structures & Market Entry
Japan and Greater China Carve-Outs: What Recent Deals Are Telling Us